Sutro Biopharma, Inc.
STRO
$0.8578
$0.01021.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -38.31% | -56.88% | -59.64% | 230.90% | 197.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -38.31% | -56.88% | -59.64% | 230.90% | 197.83% |
| Cost of Revenue | -1,559.17% | -72.55% | -448.22% | -92.65% | -102.54% |
| Gross Profit | -1.77% | -39.19% | -27.24% | 222.56% | 275.12% |
| SG&A Expenses | -17.82% | -18.04% | -22.58% | -7.06% | -4.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.98% | 14.77% | 23.66% | 26.36% | 27.71% |
| Operating Income | -56.00% | -121.30% | -167.09% | 28.41% | 33.18% |
| Income Before Tax | -93.23% | -149.95% | -154.06% | 36.41% | 24.85% |
| Income Tax Expenses | -86.76% | -86.72% | -87.01% | 563.10% | 3,133.33% |
| Earnings from Continuing Operations | -67.70% | -113.31% | -112.99% | 28.12% | 12.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.70% | -113.31% | -112.99% | 28.12% | 12.76% |
| EBIT | -56.00% | -121.30% | -167.09% | 28.41% | 33.18% |
| EBITDA | -59.51% | -129.62% | -180.41% | 29.75% | 35.02% |
| EPS Basic | -36.94% | -57.60% | -67.78% | 44.21% | 25.39% |
| Normalized Basic EPS | -27.59% | -57.24% | -104.78% | 40.20% | 35.83% |
| EPS Diluted | -36.94% | -57.60% | -67.78% | 44.21% | 25.39% |
| Normalized Diluted EPS | -27.59% | -57.24% | -104.78% | 40.20% | 35.83% |
| Average Basic Shares Outstanding | 25.73% | 35.14% | 27.68% | 20.67% | 15.65% |
| Average Diluted Shares Outstanding | 25.73% | 35.14% | 27.68% | 20.67% | 15.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |